

Lung cancer is the world's most prevalent type of cancer, ranking first in both incidence and mortality. In 2019, there were 821,600 new cases in China and 228,100 new cases in the United States; however, the 5-year survival rate of lung cancer is approximately 20%, reflecting a considerable demand for improved precision medicine in the diagnosis and treatment of lung cancer.

Since the release of the last edition of *Lung Cancer*, published by AME Publishing Company, a new reality in lung cancer treatment has formed: sequential targeted therapy is a core treatment and combined immunotherapy is becoming a standard approach. Immunotherapy, in particular, is thriving, with a large number of studies presenting promising clinical effects. Therefore, our latest edition provides a summary of the latest developments and reports concerning these newly developed therapies.

As the proverb says, “lands apart, sky shared”; the emergence of transnational cooperation in the COVID-19 epidemic has revealed the importance of knowledge exchange. Here, we would like to provide global oncologists and researchers with a platform for academic sharing and literature review in the fight to defeat humanity's deadliest foe, lung cancer.

**Yayi He, PhD, MD**

*Department of Medical Oncology,  
Shanghai Pulmonary Hospital,  
Tongji University School of Medicine,  
Shanghai, China*